Cormedix Stock Price, News & Analysis

CorMedix (NASDAQ:CRMD) reported strong Q2 2025 financial results, highlighted by $39.7 million in net revenue from DefenCath sales, compared to $0.8 million in the same period last year. The company achieved net income of $19.8 million ($0.29 per share), a significant turnaround from a net loss of $14.2 million in Q2 2024.

For the first half of 2025, CorMedix recorded $78.8 million in net revenue and net income of $40.5 million ($0.60 per share). The company maintains a strong financial position with $190.7 million in cash and short-term investments. Operating expenses increased 18% year-over-year to $18.3 million in Q2 2025.

In a significant strategic move, CorMedix announced the acquisition of Melinta Therapeutics LLC, with an expected closing date of September 1, 2025.

CorMedix (NASDAQ:CRMD) has announced a transformational acquisition of Melinta Therapeutics for $300 million in upfront consideration, including $260M in cash and $40M in CRMD equity. The deal adds seven marketed products to CorMedix's portfolio and is expected to generate pro forma 2025 combined revenues of $305-335 million.

The acquisition brings significant strategic value with expected annual run-rate synergies of $35-45 million and is projected to be accretive to EPS with double-digit accretion in 2026. The deal includes potential additional payments of up to $25 million in regulatory milestones and royalties on REZZAYO™ and MINOCIN® sales.

The transaction is expected to close by September 1, 2025, subject to HSR Act requirements. Melinta's portfolio, which generated $120 million in 2024 revenue, includes key products like REZZAYO™, which has potential peak sales exceeding $200 million in its expanded indication.

CorMedix (NASDAQ:CRMD), a biopharmaceutical company, has announced the pricing of its public offering of 6,604,507 shares of common stock. The offering is expected to generate gross proceeds of approximately $85 million. The company has also granted underwriters a 30-day option to purchase up to an additional 15% of shares.

The offering is expected to close around June 30, 2025, with RBC Capital Markets acting as sole bookrunner. CorMedix plans to use the proceeds for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions.

CorMedix (NASDAQ:CRMD), a biopharmaceutical company, has announced plans for a $85.0 million public offering of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions.

RBC Capital Markets is serving as the sole bookrunner for the offering. The proceeds will be used for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions such as acquisitions, joint ventures, or collaborations.

CorMedix (NASDAQ: CRMD) announces a significant expansion in its Large Dialysis Organization (LDO) customer implementation of DefenCath. The customer will begin implementing DefenCath in the second half of 2025, targeting 50% more patients than initially planned. Due to this expansion and other positive developments, CorMedix has increased its Q2 net sales guidance from $31 million to $35-40 million range. The company expects modest revenue contribution starting June 2025, with growth anticipated in the latter half of the year. The implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections.

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will be held in New York from June 3-5, 2025. The company is scheduled to deliver a presentation on Thursday, June 5, 2025, at 3:45 p.m. EDT. A webcast of the presentation will be made available for interested parties.

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The event will be held in New York from May 20-21, 2025. The company will engage in a fireside chat format presentation scheduled for Wednesday, May 21, 2025, at 3:05 p.m. EDT. A webcast link will be available for interested parties to follow the presentation.

CorMedix Inc. (CRMD) reported strong Q1 2025 financial results with net revenue of $39.1 million and net income of $20.6 million ($0.32 per share), compared to a net loss in Q1 2024. The company achieved adjusted EBITDA of $23.6 million and positive cash flow from operations of $19.7 million. DefenCath sales drove performance, particularly in outpatient dialysis. The inpatient sales team is now fully operational, with institutional shipments doubling over three months. CorMedix commenced a Phase 3 study for reducing CLABSIs in TPN patients. The company expects to hit the high end of its H1 2025 sales guidance ($62-70 million) and reported cash and short-term investments of $77.5 million, sufficient for at least 12 months of operations.

CorMedix (Nasdaq: CRMD), a biopharmaceutical company developing therapeutic products for life-threatening diseases, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.

The company will host a corporate update conference call at 8:30am Eastern Time on the same day. Interested parties can join through:

• Domestic call-in: 1-844-676-2922
• International call-in: 1-412-634-6840
• Conference ID: 10198548
• Webcast available via provided link